1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biocure Technology Inc.

Biocure Technology Inc.

BICTF
Biocure Technology Inc.US flagOther OTC
0.01
USD
- -
- -
379,088.00Market Cap
2015 Y
2016 Y
2016 Y
2017 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.02
-0.42
- -
-0.46
-0.62
-0.44
-0.27
-0.1
-0.12
-0.18
-0.03
-0.01
-0.01
Free Cash Flow per Basic Share
-0.01
-0.01
-0.29
-0.01
-0.22
-0.33
-0.35
-0.12
-0.09
-0.07
-0.02
- -
- -
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.18
-0.19
-1.79
-0.17
0.16
-0.28
-0.55
-0.7
-0.67
-0.76
-0.57
-0.59
-0.38
-0.46
Tangible Book Value per Share
0.42
0.41
-0.06
0.41
0.28
0.08
-0.04
-0.21
-0.07
-0.2
0.16
0.13
0.1
0.12
Basic Weighted Avg Shares
4
4
5
5
10
11
11
11
11
12
10
10
16
13
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
-17,053.71
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-2
- -
-5
-7
-5
-3
-1
-1
-2
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-35,299.35
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
-2
-2
-4
-2
-4
- -
-1
- -
- -
LT Debt
- -
- -
- -
- -
- -
1
3
3
1
- -
- -
- -
- -
- -
Total Equity
2
2
- -
2
3
1
- -
-2
-1
-2
2
1
2
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
20
20
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
- -
- -
Payables & Accruals
1
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-54.33%
-11.55%
17.55%
Free Cash Flow
298.37%
-175.94%
-658%
Net Income, GAAP
5,444.99%
-30.88%
-60.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.03
0.24
-0.01
- -
-0.18
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Yee Sing Cheng
Sector
Healthcare
Industry
Biotechnology
Address
1055 West Hastings Street Vancouver BC Canada V6E 2E9
IPO Date
Nov 28, 2018
Website
biocuretech.com
Similar Companies
Ascendis Pharma A/S (ASND)
Duality Biotherapeutics, Inc. (9606.HK)
Spruce Biosciences, Inc. (SPRB)
IXICO plc (IXI.L)
Philogen S.p.A. (PHIL.MI)
OS Therapies Incorporated (OSTX)
Business
Biocure Technology Inc. is a biopharmaceutical company specializing in the development and commercialization of biosimilars and CAR-T cell therapies targeting cancers and other diseases; its core products include biosimilar candidates for Interferon Beta 1b to treat multiple sclerosis, PEG-Filgrastim and Filgrastim for chemotherapy-induced neutropenia and blood disorders, and Ranibizumab for age-related macular degeneration and vision loss; the company also advances proprietary CAR-T cell immunotherapy, notably BCP401, for acute leukemia, chronic lymphocytic leukemia, solid tumors including lung, breast, and pancreatic cancers, with preclinical trials demonstrating high remission rates and low toxicity in animal models. Founded in 2005 and headquartered in Vancouver, Canada, Biocure operates primarily through its South Korean subsidiary Biocure Pharm with research and manufacturing focused in Asia; it maintains joint ventures and partnerships across Asia and Europe for clinical development and planned trials. Recent developments include a December 2024 private placement financing of $200,000 to support operations, an extension of its exclusive letter agreement in 2024 to acquire Atriva Therapeutics GmbH via reverse takeover for respiratory disease assets though the transaction remains pending as of late 2024, and ongoing preclinical advancements for CAR-T therapies with IND submissions targeted for clinical trials.

Company News

APIChat

  • thenewswire.com

    Biocure Technology Inc. Announces Adoption of Semi-Annual Reporting

  • newsfilecorp.com

    CSE Bulletin: Consolidation - Biocure Technology Inc. (CURE.X)

  • globenewswire.com

    Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

  • newsfilecorp.com

    Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction

  • newsfilecorp.com

    BioCure Technology Inc. Announces New President, Appointment of Capital Markets Advisor and Grant of Stock Options

  • newsfilecorp.com

    BioCure Technology Inc. Announces Closing of Financing

  • newsfilecorp.com

    BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)